Drugs / HS-10383
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06092983 | Jun → Dec 2023 | — | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05429723 | Mar → Jun 2022 | cough variant asthma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06246565 | Mar 2024 → Sep 2025 | — | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-11 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results HANSOH PHARMA ANNOUNCES POSITIVE PHASE 1 CLINICAL TRIAL RESULTS WITH HS-10383 ONCE-DAILY ORAL P2X3 ANTAGONIST FOR THE TREATMENT OF CHRONIC COUGH hspharm.com ↗
Hansoh Pharma (03692.HK) announces that the positive topline clinical results from Phase I multiple dose-ascending (MAD) study of HS-10383, a highly selective P2X3 antagonist, in healthy Chinese subjects will be presented at the Asian Pacific Society of Respirology conference in Hong Kong, from November 7 to 10. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-11 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | HANSOH PHARMA ANNOUNCES POSITIVE PHASE 1 CLINICAL TRIAL RESULTS WITH HS-10383 ONCE-DAILY ORAL P2X3 ANTAGONIST FOR THE TREATMENT OF CHRONIC COUGH hspharm.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10383 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06092983 ↗ |
| Action | Inhibit | “selective P2X3 receptor antagonist” NCT05429723 ↗ |
| Route | Oral | “HS-10383 administered orally to healthy volunteers.” NCT05429723 ↗ |